JPH05186357A - 飲食物消化分解産物吸収抑制手段 - Google Patents
飲食物消化分解産物吸収抑制手段Info
- Publication number
- JPH05186357A JPH05186357A JP3359568A JP35956891A JPH05186357A JP H05186357 A JPH05186357 A JP H05186357A JP 3359568 A JP3359568 A JP 3359568A JP 35956891 A JP35956891 A JP 35956891A JP H05186357 A JPH05186357 A JP H05186357A
- Authority
- JP
- Japan
- Prior art keywords
- sodium polyacrylate
- food
- aqueous liquid
- active ingredient
- drink
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 235000013361 beverage Nutrition 0.000 title description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 29
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 29
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 230000002378 acidificating effect Effects 0.000 claims abstract description 18
- 206010010774 Constipation Diseases 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 208000019423 liver disease Diseases 0.000 claims description 8
- 230000005976 liver dysfunction Effects 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 22
- 210000002784 stomach Anatomy 0.000 abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 6
- 235000012054 meals Nutrition 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- 239000011668 ascorbic acid Substances 0.000 abstract description 4
- 229960005070 ascorbic acid Drugs 0.000 abstract description 4
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 244000248349 Citrus limon Species 0.000 abstract description 3
- 235000005979 Citrus limon Nutrition 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 208000027700 hepatic dysfunction Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 235000015203 fruit juice Nutrition 0.000 abstract 1
- 230000035622 drinking Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 17
- 230000009102 absorption Effects 0.000 description 13
- 230000029087 digestion Effects 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000003914 Cholinesterases Human genes 0.000 description 3
- 108090000322 Cholinesterases Proteins 0.000 description 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000005523 excessive nutrition Nutrition 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3359568A JPH05186357A (ja) | 1991-12-31 | 1991-12-31 | 飲食物消化分解産物吸収抑制手段 |
| AU30455/92A AU3045592A (en) | 1991-12-31 | 1992-12-30 | Inhibitor for absorption of digested and decomposed products of food and drink |
| GB9227128A GB2262888B (en) | 1991-12-31 | 1992-12-30 | Inhibitor for absorption of digested and decomposed products of food and drink |
| FR929215947A FR2685611B1 (fr) | 1991-12-31 | 1992-12-30 | Inhibiteur d'absorption de produits digeres et decomposes d'aliments et de boissons. |
| CH3987/92A CH684740A5 (de) | 1991-12-31 | 1992-12-30 | Absorptionsinhibitor für Verdauungs- und Zersetzungsprodukte von Nahrungsmitteln und Getränken. |
| CA002086566A CA2086566A1 (en) | 1991-12-31 | 1992-12-31 | Inhibitor for absorption of digested and decomposed products of food and drink |
| DE4244588A DE4244588A1 (enrdf_load_stackoverflow) | 1991-12-31 | 1992-12-31 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3359568A JPH05186357A (ja) | 1991-12-31 | 1991-12-31 | 飲食物消化分解産物吸収抑制手段 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05186357A true JPH05186357A (ja) | 1993-07-27 |
Family
ID=18465171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3359568A Pending JPH05186357A (ja) | 1991-12-31 | 1991-12-31 | 飲食物消化分解産物吸収抑制手段 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH05186357A (enrdf_load_stackoverflow) |
| AU (1) | AU3045592A (enrdf_load_stackoverflow) |
| CA (1) | CA2086566A1 (enrdf_load_stackoverflow) |
| CH (1) | CH684740A5 (enrdf_load_stackoverflow) |
| DE (1) | DE4244588A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2685611B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2262888B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522082A (ja) * | 2003-04-05 | 2006-09-28 | アストラゼネカ アクチボラグ | 便秘症の処置または予防用のｉｂａｔ阻害剤の使用 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| ATE349214T1 (de) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
| US20130225511A1 (en) | 2010-11-04 | 2013-08-29 | Per-Göran Gillberg | Ibat inhibitors for the treatment of liver diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| KR102811961B1 (ko) | 2018-06-20 | 2025-05-22 | 알비레오 에이비 | 오데빅시바트의 결정 변형물 |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| KR20210126053A (ko) | 2019-02-06 | 2021-10-19 | 알비레오 에이비 | 벤조티아디아제핀 화합물 및 담즙산 조절제로서의 그의 용도 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP7665620B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2221139B1 (enrdf_load_stackoverflow) * | 1973-03-13 | 1978-03-24 | Nippon Kayaku Kk | |
| DE3307816A1 (de) * | 1983-03-02 | 1984-09-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandin-haltiges pharmazeutisches praeparat und seine herstellung |
| GB8419245D0 (en) * | 1984-07-27 | 1984-08-30 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| JPS61172815A (ja) * | 1985-01-28 | 1986-08-04 | Toshiyuki Nakajima | 潤滑剤 |
| GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
| GB8910076D0 (en) * | 1989-05-03 | 1989-06-21 | Thackray C F Ltd | Sterilisable lubricant |
| JPH03120227A (ja) * | 1989-10-02 | 1991-05-22 | Shigeo Ochi | 飲食物消化分解産物吸収抑制剤 |
-
1991
- 1991-12-31 JP JP3359568A patent/JPH05186357A/ja active Pending
-
1992
- 1992-12-30 AU AU30455/92A patent/AU3045592A/en not_active Abandoned
- 1992-12-30 FR FR929215947A patent/FR2685611B1/fr not_active Expired - Fee Related
- 1992-12-30 GB GB9227128A patent/GB2262888B/en not_active Expired - Fee Related
- 1992-12-30 CH CH3987/92A patent/CH684740A5/de not_active IP Right Cessation
- 1992-12-31 CA CA002086566A patent/CA2086566A1/en not_active Abandoned
- 1992-12-31 DE DE4244588A patent/DE4244588A1/de not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522082A (ja) * | 2003-04-05 | 2006-09-28 | アストラゼネカ アクチボラグ | 便秘症の処置または予防用のｉｂａｔ阻害剤の使用 |
| JP2011173925A (ja) * | 2003-04-05 | 2011-09-08 | Albireo Ab | 便秘症の処置または予防用のｉｂａｔ阻害剤の使用 |
| JP4870552B2 (ja) * | 2003-04-05 | 2012-02-08 | アルビレオ・アクチボラグ | 便秘症の処置または予防用のｉｂａｔ阻害剤の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4244588A1 (enrdf_load_stackoverflow) | 1993-07-15 |
| FR2685611B1 (fr) | 1994-06-10 |
| GB9227128D0 (en) | 1993-02-24 |
| CA2086566A1 (en) | 1993-07-01 |
| CH684740A5 (de) | 1994-12-15 |
| FR2685611A1 (fr) | 1993-07-02 |
| GB2262888B (en) | 1996-07-24 |
| AU3045592A (en) | 1993-07-08 |
| GB2262888A (en) | 1993-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05186357A (ja) | 飲食物消化分解産物吸収抑制手段 | |
| JP3850891B2 (ja) | 緩下効果を有する組成物 | |
| US20100316768A1 (en) | Nutritionally Fortified Liquid Composition With Added Value Delivery Systems/Elements/Additives | |
| DE69630694T2 (de) | Neutralisierung von sauren nahrungs- und arzneimitteln | |
| JP2983503B2 (ja) | 高い生物学的利用能をもつ鉄‐カルシウムミネラル補給物 | |
| TW200812503A (en) | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass | |
| CN105249072B (zh) | 膳食纤维型可吸果冻功能饮料的配方及其制备方法 | |
| AU2015253178B2 (en) | Foods, systems, methods, and kits for providing electrolyte replacement | |
| JPH05255097A (ja) | 液状組成物 | |
| JP5414995B2 (ja) | フコイダンを有効成分とする酸性尿改善飲食物および経口投与用医薬組成物 | |
| Smith et al. | Dietary concerns associated with the use of medications | |
| JPH0272843A (ja) | 糖アルコールを含有するミネラル補給剤 | |
| JP3489095B2 (ja) | 健康食品及び健康飲料 | |
| JP2000189109A (ja) | 液状食品 | |
| JP3884611B2 (ja) | 衝動性疾患の改善剤 | |
| JPH10306028A (ja) | 脂質消化吸収阻害整腸剤 | |
| US20020137729A1 (en) | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride | |
| WO2001091730A1 (en) | Mineral supplement | |
| JP4460234B2 (ja) | ダイエット食品 | |
| JPH06507393A (ja) | 水溶性高粘度品位セルロースエーテルの薬剤組成物とその使用 | |
| US8993639B2 (en) | Compound and method for treatment of gastroesophageal reflux | |
| JP4435882B2 (ja) | アルコール吸収抑制組成物 | |
| US20050214362A1 (en) | Appetite suppressant | |
| TW200800152A (en) | Antifatigue composition | |
| US10639328B1 (en) | Compositions and methods for reducing hyperglycemia and treating diabetes |